Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...
Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...
Elon Musk validated the use of GLP-1 drugs in a post on X on Wednesday. But Robert F. Kennedy Jr. has said he's opposed to Americans using them to fight obesity.
OneSource has clients in America, Europe, the Middle East, Africa, and India, all looking at GLP-1 opportunities. The market ...
But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...
With several of these drugs going off patent in the next few years, OneSource is poised to see big growth in the generic ...
Drugs used to treat diabetes and obesity, or GLP-1 (Glucagon-like peptide-1), will be a significant growth driver for ...
The EMA approved a kidney disease–related label expansion for the blockbuster GLP-1 drug after a study showed reduced risk of ...
Barriers to accessing GLP-1 medications are beginning to break down as drug manufacturers, insurers, and lawmakers look to expand availability, lower costs, and address continued high demand.
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...
StudyFinds on MSN5h
Scientists close to creating ‘simple pill’ that cures diabetesImagine a world where diabetes could be treated with a simple pill that essentially reprograms your body to produce insulin ...
That, according to the firm, make them particularly suitable for users of GLP-1 medications. GLP-1 drugs such as Ozempic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback